Journal of Medicinal Chemistry p. 4913 - 4925 (2016)
Update date:2022-07-29
Topics:
Wang, Heng-Yen
Qin, Yajuan
Li, Huiying
Roman, Linda J.
Martásek, Pavel
Poulos, Thomas L.
Silverman, Richard B.
Neuronal nitric oxide synthase (nNOS) is an important therapeutic target for the treatment of various neurodegenerative disorders. A major challenge in the design of nNOS inhibitors focuses on potency in humans and selectivity over other NOS isoforms. Here we report potent and selective human nNOS inhibitors based on the 2-aminopyridine scaffold with a central pyridine linker. Compound 14j, the most promising inhibitor in this study, exhibits excellent potency for rat nNOS (Ki = 16 nM) with 828-fold n/e and 118-fold n/i selectivity with a Ki value of 13 nM against human nNOS with 1761-fold human n/e selectivity. Compound 14j also displayed good metabolic stability in human liver microsomes, low plasma protein binding, and minimal binding to cytochromes P450 (CYPs), although it had little to no Caco-2 permeability.
View MoreShandong Zhongcheng Barium Salt Co., Ltd
Contact:+86-15725732638
Address:No.29 baoxi road, hi-tech zone, zibo, shandong
Changsha Huajing Powdery Material Technological Co., Ltd.
Contact:86-731-88879686
Address:Building 2, West Garden, Main Campus of Central South University, Changsha, Hunan Province, China
Beijing ZhongDaXinHe Chemical Product Co.,Ltd(expird)
Contact:010-52876516
Address:tongzhoubeiyuan
Shanghai Sunway Pharmaceutical Technology Co.,Ltd.
Contact:+86-21-5161 3915
Address:Shanghai YangPu
QINGDAO DEVELOP chemistry Co.,Limited
Contact:+86-532-85807910
Address:98#Nanjing Road, Qingdao, China 266071
Doi:10.1055/s-2001-16773
(2001)Doi:10.1002/chem.201304063
(2014)Doi:10.1039/f19827800347
(1982)Doi:10.1016/S0040-4039(01)84944-3
(1972)Doi:10.1021/ja01609a033
(1955)Doi:10.1016/j.jinorgbio.2010.03.013
(2010)